<DOC>
	<DOCNO>NCT00005797</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy drug total-body irradiation donor bone marrow transplant help stop growth cancer cell . It also help stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . PURPOSE : This phase II trial study well donor bone marrow transplant work treat patient hematologic cancer .</brief_summary>
	<brief_title>Bone Marrow Transplant Treating Patients With Hematologic Cancers</brief_title>
	<detailed_description>OBJECTIVES : - Determine progression free survival ( PFS ) overall survival ( OS ) patient low risk myeloid disorder older allogeneic recipient treat high dose busulfan cyclophosphamide allogeneic bone marrow transplantation ( BMT ) . - Determine PFS OS patient lymphoid high risk myeloid disorder treat etoposide , total body irradiation , allogeneic BMT . - Evaluate toxicity 2 regimen combine cyclosporine methotrexate graft versus host disease prophylaxis patient . - Evaluate PFS OS allogeneic BMT patient multiple myeloma chronic lymphocytic leukemia . OUTLINE : - Regimen A : Patients chronic myelogenous leukemia ( CP1 , AP/CP2 ) myeloproliferative disorder , myelodysplastic disorder , acute myelogenous leukemia ( CR1 ) , multiple myeloma ( eligible receive total body irradiation due prior radiation ) treat high dose busulfan cyclophosphamide follow allogeneic bone marrow transplantation ( BMT ) . Patients receive oral busulfan every 6 hour day -7 -4 cyclophosphamide IV 1 hour day -3 -2 . Allogeneic bone marrow infuse day 0 . - Regimen B : Patients acute myelogenous leukemia ( least CR2 , relapse ) , acute lymphoid leukemia ( ALL ) , acute leukemia CNS involvement , multiple myeloma , chronic lymphocytic leukemia treat total body irradiation etoposide follow allogeneic BMT . Patients receive total body irradiation ( TBI ) day -7 -4 total 11 fraction etoposide IV 4 hour day -3 . Male patient ALL receive testicular boost 2 fraction 2 successive day TBI . Allogeneic bone marrow infuse day 0 . Patients regimens receive cyclosporine methotrexate graft versus host disease prophylaxis . Patients follow weekly 3 month monthly 1 year . PROJECTED ACCRUAL : At least 50 patient low risk myeloid disease , 50 patient lymphoid malignancy , 60 patient high risk myeloid disease accrue study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis : Acute myelogenous leukemia Complete remission ( CR ) 1 ALL except good cytogenetics define [ ( inv16 , ( 8,21 ) , ( 15,17 ) ] CR2 Induction failure Relapsed OR Acute lymphocytic leukemia ( ALL ) CR1 high risk define overt CNS involvement , 1 risk factor ( age 30 , WBC least 20,000/mm^3 , least 4 week CR1 , myeloid phenotype ) CR2 Induction failure Relapsed OR Chronic myelogenous leukemia Chronic phase ( CP ) 1 Accelerated phase ( AP ) /CP2 OR Chronic lymphocytic leukemia At diagnosis RAI stage III/IV Binet C Must undergo 1 induction regimen Relapsed stage Must receive 3 regimen diagnosis OR Multiple myeloma At diagnosis stage II/III ( primary refractory sensitive ) Relapsed 2 time sensitive disease Plasma cell leukemia OR Myelodysplasia All subtypes eligible OR Myeloproliferative disorder Poor response medical therapy OR Cytogenetic abnormality Must relate donor genotypic 6 6 HLA A , B , DR match Molecular DR matching require PATIENT CHARACTERISTICS : Age : 15 55 Performance status : Karnofsky 80100 % Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Bilirubin great 2.0 mg/dL SGOT/SGPT great 3 time upper limit normal PT/PTT normal Renal : Creatinine great 2.0 mg/dL Creatinine clearance least 60 mL/min Cardiovascular : LVEF least 45 % MUGA scan echocardiography No myocardial infarction within past 6 month No arrhythmia control therapy Pulmonary : FEV_1 least 50 % predict DLCO least 50 % predict Other : Not pregnant nursing Negative pregnancy test No diabetes mellitus thyroid disease medically control No psychosocial disorder would preclude study compliance No active serious infection HIV negative Donor must HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>refractory anemia</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>refractory cytopenia multilineage dysplasia</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL1 negative</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>